The $2,000 Part D Cap in Year Two

Updated September 2026 · 15 min read

The Old Structure: Why It Had to Change

For two decades, Medicare Part D had one of the most confusing benefit structures in American healthcare. Created in 2003 and launched in 2006, Part D's original design included four distinct coverage phases that left many beneficiaries exposed to thousands in out-of-pocket costs:

The most punishing aspect of the old design was the catastrophic phase. Beneficiaries who needed expensive specialty drugs — cancer treatments, biologics for autoimmune conditions, medications for rare diseases — could face 5% coinsurance with no annual limit. When a single drug costs $15,000 per month, 5% adds up fast. Some beneficiaries were paying $10,000 to $15,000 per year out of pocket on drugs alone.

The New Structure: What Changed

The Inflation Reduction Act of 2022 overhauled Part D's benefit structure effective January 1, 2025. The centerpiece: a hard $2,000 annual cap on out-of-pocket prescription drug spending. Once a beneficiary hits the cap, their plan, the manufacturer, and Medicare cover 100% of remaining drug costs for the year. The cap is indexed to Part D cost growth, so it rose to $2,100 in 2026, the cap's second full year in effect.

The redesign also restructured who pays what across the coverage phases. In the catastrophic phase, plans now bear 60% of costs (up from 15%) and Medicare covers 20% (down from 80%). Manufacturer discounts in the coverage gap shifted from 70% to 20%. These changes shifted billions in costs from beneficiaries and the government onto plans and manufacturers — a structural change with significant market implications.

Year Two: The Impact by the Numbers

In 2026, the redesign's second year, an estimated 18.7 million Medicare beneficiaries are paying less for prescription drugs than they would have under the old Part D structure. Most of them never come close to the cap. They save because the coverage gap is gone and the benefit is simpler and more predictable, which also lets more people spread costs through the Medicare Prescription Payment Plan.

The largest savings go to a much smaller group. About 1.5 million beneficiaries used to pay more than the cap each year, and they now stop paying for covered drugs once they reach it. Those beneficiaries save an average of $1,500 per year compared with the old structure, or an estimated $2.25 billion a year in total.

One of the most significant findings: medication adherence improved by 12% among beneficiaries who previously faced high out-of-pocket costs. When people know their drug costs are capped, they're more likely to fill prescriptions and take medications as directed — leading to better health outcomes and potentially lower overall healthcare spending.

Drug Price Negotiation: The Other Half of the Equation

The $2,000 cap limits what beneficiaries pay, but the IRA's drug price negotiation program reduces what Medicare pays. The first 10 negotiated drug prices took effect January 1, 2026, with discounts of 38% to 79% on drugs that previously cost Medicare $50.5 billion annually. See our full analysis: Drug Price Negotiation 2026.

Together, the cap and negotiation work synergistically. Lower negotiated prices mean beneficiaries reach the cap more slowly (spending less total before hitting it), and the program saves money on the back end by paying less for the drugs themselves. CMS estimated the first 10 negotiated prices would save Medicare about $6 billion a year, and CBO projects negotiation will save nearly $100 billion over 10 years. Negotiated prices for 15 more Part D drugs, including Ozempic and Wegovy, take effect in January 2027, bringing the program to 25 drugs. The negotiated prices are published on CMS.gov.

The Premium Impact: What Beneficiaries Are Paying

The redesign isn't free. Average Part D premiums rose approximately 7% in 2026, from $34.70 to $37.13 per month. This increase reflects the new cost structure: plans now bear significantly more financial risk in the catastrophic phase, and they're passing some of that cost through to beneficiaries via higher premiums.

However, context matters. A $2.43/month premium increase translates to about $29 more per year. For the 1.5 million beneficiaries who save an average of $1,500, that's an extraordinary return. Even for beneficiaries with low drug costs, the premium increase provides insurance against catastrophic drug expenses — a protection that didn't exist before.

That said, the premium trajectory bears watching. Industry analysts project Part D premiums could rise another 5-8% in 2027 as plans fully absorb the new cost structure. Congress also allocated $47 billion in subsidies over 10 years to limit premium increases — but those subsidies are time-limited, and there's no guarantee they'll be extended.

The Medicare Prescription Payment Plan

Another IRA provision that took effect in 2025: the Medicare Prescription Payment Plan, which allows beneficiaries to spread their out-of-pocket drug costs into predictable monthly installments. Instead of facing a bill for the full cap at the pharmacy in January, beneficiaries can opt to pay roughly $167–$175/month throughout the year.

Early data shows strong uptake: approximately 820,000 beneficiaries have enrolled in the payment plan since it launched. The program has been particularly popular among beneficiaries on fixed incomes who take expensive medications early in the year — cancer patients starting a new treatment regimen, for example, or those with autoimmune conditions whose biologics cost thousands per dose.

The payment plan addresses a critical behavioral barrier: cost-related non-adherence. Research consistently shows that high upfront costs at the pharmacy counter cause many beneficiaries to abandon prescriptions or skip doses. By smoothing costs into predictable monthly amounts, the payment plan reduces this barrier and improves medication adherence — which in turn reduces hospitalizations and emergency visits.

Implementation hasn't been without challenges. Pharmacies have had to update their systems to process payment plan transactions, and some beneficiaries have reported confusion about enrollment. CMS has conducted outreach campaigns, including partnerships with pharmacies, SHIP counselors, and community organizations, to increase awareness and enrollment.

Winners and Losers

Real Stories: How the Cap Changed Lives

The statistics are compelling, but the human impact is where the redesign matters most. Consider the types of beneficiaries who have benefited:

Cancer patients on oral chemotherapy: A beneficiary taking Ibrance (palbociclib) for metastatic breast cancer previously faced annual out-of-pocket costs of approximately $8,400. Under the new structure, they pay $2,000 — a savings of $6,400 per year. For a senior on a fixed income, that's the difference between affording treatment and skipping doses.

Autoimmune patients on biologics: A beneficiary taking Humira (adalimumab) for rheumatoid arthritis previously paid approximately $5,200 per year out of pocket. With the $2,000 cap, they save $3,200 annually — and with biosimilar competition driving prices down further, the savings are even greater.

Multiple sclerosis patients: MS drugs are among the most expensive in Medicare Part D, with annual costs exceeding $80,000. Under the old structure, a beneficiary could face $4,000-$6,000 in annual out-of-pocket costs. The $2,000 cap provides meaningful relief for this population.

Diabetes patients on multiple medications: While insulin is separately capped at $35/month (since 2023), many diabetes patients take additional medications — SGLT2 inhibitors, GLP-1 agonists, and others — that add up. The $2,000 cap provides a ceiling on these combined costs.

Impact on Plan Markets and Competition

The redesign has reshaped the Part D plan marketplace. With plans now bearing 60% of catastrophic-phase costs (up from 15%), the economics of offering Part D coverage have fundamentally changed. Plans have responded in several ways:

• Formulary tightening: Some plans have restricted their formularies, moving expensive drugs to higher tiers or requiring step therapy
• Premium adjustments: The 7% average increase masks wider variation — some plans raised premiums 15-20% while others held steady
• Plan exits: 14 standalone Part D plans left the market, reducing competition in some areas
• MA-PD growth: Medicare Advantage plans with drug coverage have become more competitive, as they can spread Part D risk across their broader MA business
• Specialty pharmacy partnerships: Plans are increasingly steering beneficiaries toward specialty pharmacies and mail-order options to control costs

How the Pharmaceutical Industry Has Responded

Drugmakers now pay directly for the cap. In 2025, the IRA replaced the old Coverage Gap Discount Program with a new Manufacturer Discount Program. Manufacturers owe a 10% discount on brand-name drugs in the initial coverage phase and a 20% discount in the catastrophic phase. Under the old design, manufacturer discounts applied only in the coverage gap, so drugmakers had little exposure once a patient reached catastrophic coverage. Now they share in the cost of every high-spending beneficiary, which gives them a direct financial stake in the cap.

The industry has responded on several fronts:

• Litigation: Manufacturers and trade groups filed a series of lawsuits against the IRA's drug provisions. Federal courts have so far rejected every challenge, and both the negotiated prices and the redesigned benefit remain in effect.
• Launch pricing: Analysts have documented higher list prices for newly launched drugs. Because manufacturers can't easily raise prices on existing drugs in Medicare (the IRA's inflation rebates penalize increases above inflation), launch prices are where they have the most room.
• Lobbying to narrow the law: The industry has pushed Congress to change how negotiation applies to small-molecule drugs (the so-called "pill penalty") and to orphan drugs. In 2025, Congress broadened the orphan-drug exclusion from negotiation.
• R&D messaging: Drugmakers argue that the cap and negotiation together will reduce investment in new therapies. So far, industry R&D spending has stayed high, but it's too early to measure effects on the long-run drug pipeline.

The net effect on premiums runs through the plans. Insurers now carry 60% of catastrophic-phase costs (up from 15%) and have raised premiums and tightened formularies in response. Manufacturer discounts and CMS premium subsidies have limited those increases so far. How long that holds depends on whether federal subsidies continue after the transition period.

Concerns and Criticisms

The redesign isn't without critics. Several legitimate concerns have emerged in its first two years that deserve attention:

While the benefits for high-cost beneficiaries are clear, the broader systemic effects are more nuanced — and some may take years to fully materialize.

Premium trajectory: The 7% premium increase is just the beginning. As plans fully absorb the higher catastrophic-phase costs, premiums could continue to rise. Without ongoing congressional subsidies, beneficiaries could face double-digit premium increases in future years.

Taxpayer cost shift: Congress allocated $47 billion in subsidies to cushion the transition. Critics argue this represents a significant transfer of costs from beneficiaries to taxpayers — and question whether it's sustainable long-term, particularly given Medicare's existing fiscal challenges.

Plan market exits: At least 14 standalone Part D plans exited the market for 2026, citing the unfavorable economics of the new cost structure. While beneficiaries in those areas still have plan options, reduced competition could lead to higher premiums and narrower formularies over time.

Manufacturer cost-shifting: With new discount obligations, some drug manufacturers have responded by adjusting launch prices for new drugs upward — potentially offsetting some of the savings from the cap and negotiation provisions.

Low-Income Beneficiaries: Extra Help and LIS

The Part D redesign interacts with the existing Low-Income Subsidy (LIS) program, also known as "Extra Help." Approximately 13 million beneficiaries receive LIS, which covers most or all of their Part D premiums, deductibles, and copayments. For these beneficiaries, the $2,000 cap has limited direct impact since their out-of-pocket costs were already minimal.

However, the IRA expanded LIS eligibility from 135% to 150% of the federal poverty level, adding an estimated 400,000 new beneficiaries to the program. This expansion — combined with the $2,000 cap for those just above the LIS threshold — has significantly reduced the "cliff effect" where beneficiaries slightly above the income cutoff faced dramatically higher drug costs than those just below it.

The interaction between LIS and the Part D redesign also affects plan economics. Plans with high LIS enrollment face different financial dynamics than those serving a predominantly non-LIS population, as CMS directly subsidizes much of the drug spending for LIS beneficiaries.

Looking Ahead: 2027 and Beyond

Several developments will shape the Part D landscape in 2027 and beyond:

• 25 negotiated drugs: Negotiated prices for 15 more Part D drugs, including Ozempic, Wegovy, Ibrance, and Xtandi, take effect January 1, 2027, joining the 10 already in effect. Part B drugs join the program with the third cycle, with prices effective 2028
• Premium stabilization: Congress must decide whether to extend the transition subsidies that have limited premium increases; failure to act could result in 15-20% premium spikes
• Biosimilar competition: Several major biologics face biosimilar competition in 2027-2028, which could reduce costs across the Part D program
• GLP-1 coverage question: Whether Medicare will cover GLP-1 drugs (Ozempic, Wegovy) for obesity — at an estimated cost of $35-50 billion annually — could reshape Part D economics entirely

The Bottom Line

Nearly two years in, the data paints a clear picture: the Part D redesign has delivered meaningful financial relief to the beneficiaries who needed it most, while creating new cost pressures that will require ongoing attention.

The Part D redesign is working as intended for its primary target: beneficiaries with high drug costs. For someone who previously paid $10,000+ per year out of pocket on medications, the $2,000 cap is transformative. Medication adherence is up, financial stress is down, and health outcomes are improving.

But the question is who's picking up the tab. The cost shift to insurers, manufacturers, and taxpayers is real, and the long-term premium trajectory remains uncertain. Whether Congress renews the transition subsidies — and whether the drug price negotiation program delivers enough savings to offset the structural costs — will determine whether this redesign is sustainable or becomes yet another unfunded entitlement expansion.